Clinical Trials Browser

Phase 1 × CC 401 × Clear all

NCT00126893 2007-05-15

Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

Phase 1 Terminated

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid